|Name:||Robert H. Vonderheide, M.D., D.Phil.|
|Title/Titles:||Professor of Medicine, and Hanna Wise Professor of Cancer Research, Vice Chief of Research, Hematology-Oncology Division|
Dr. Vonderheide’s laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. His basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on melanoma and pancreatic cancer. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. more
Beatty GL, Chiorean EG. Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O’Dwyer PF, Vonderheide RH : CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, 2011, 331:1612-6.
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ : EMT and dissemination precede pancreatic tumor formation. Cell, 2012, 148:349-61.
Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell Jr DJ, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH: CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Science Transl Med, 2012, 4: 132-147.
Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH: Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell, 2012, 21:822-35.
Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL : Effect of blocking lymphocyte chemotaxis on visceral graft-vs-host disease. New England Journal of Medicine, 2012, 367:135-45.
Vonderheide RH, Bayne LJ : Inflammatory networks and immune surveillance of pancreatic carcinoma . Curr Opin Immunol 25: 200-205, 2013.
Vonderheide RH, Nathanson KL: Immunotherapy at large: the road to personalized cancer vaccines. Nat Med, 2013, 19:1098-1100.
Vonderheide RH, Glennie MJ: Agonistic CD40 antibodies and cancer therapy. Clin Can Res 19: 1035-1043, 2013.
Richman LP, Vonderheide RH: Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res, 2014, 2:
Gangadhar TC, Vonderheide RH: Mitigating the toxic effects of anti-cancer immunotherapy. Nat Rev Clin Oncol, 2014, 11:91-9.
Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, Pasca di Magliano M: CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res, 2014, 2:423-35.